Vascular disrupting agents (VDA) can overcome the multidrug resistance of tumors by targeting specifically tumor vasculature. The present invention relates to specific analogs of combretastatin in the treatment or prevention of cancer, including multidrug-resistant and combretastatin-refractory cancers. Developmental Status: Pharmacodynamical and toxicological studies currently in the works , Animal data available, Further mouse studies on tumor xenografts from other entities planned, Compound samples available for testing
Further information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
15.12.2017 | Power and Electrical Engineering
15.12.2017 | Materials Sciences
15.12.2017 | Life Sciences